Job Description
The ARM is the primary point of contact for infusion center customers. The ARM works to optimize the experience for both the patient and the account by communicating and improving operational metrics for patients on Biogen therapies. The ARMs will educate and support infusion account personnel by providing information and training on: the TYSABRI infusion process, TOUCH requirements, REMS program, reimbursement and clinical information. The ARM is responsible for pulling through the infusion capacity strategy enabling patient access to therapy. They are responsible for onboarding and training new TOUCH certified locations and ensuring REMS compliance.
NEUROLOGY ACCOUNTS
The ARM collaborates with their counterparts on Key Neurology accounts. They are tasked to resolve access escalations for the Biogen MS portfolio. This role is responsible for informing and supporting the local teams on the process to improve operational metrics such as cycle times, graduation rates, never starts, free drug conversion, etc. The ARM is responsible for deploying unique service offerings based on account needs, examples include Cover My Meds, Nurse Educator and Proactive PA Renewals. The ARM shall serve as the conduit between the Key Accounts and Patient Services to streamline and simplify access to therapy. The ARM will customize approach to meet the unique needs of each key account.
The ARM will be field based and require significant travel that may extend from 40-80% depending on the territory geography, customer requirements, meetings and required training.
The ARM must demonstrate a long-term track record of adherence to Biogen Corporate Compliance Policies.
Responsibilities include (but not limited to):
Help build trust and value within Key Accounts, infusion sites and with key internal stakeholders by acting as a subject matter expert on all aspects of reimbursement and coverage.
Improves account education of Biogen service offerings through Business Reviews, site visits, and educational dinner programs.
Builds processes unique to each Key Account that optimizes Biogen product fulfilment from the perspective of both the patient and the account; continuously reevaluates and optimizes processes as needed.
Conduct External Business Reviews focused on operational metrics for Infusion Accounts and Key Neurology Accounts.
Educate on requirements of TOUCH Program with prescribers, infusion accounts, and central pharmacies, and identify opportunities to prevent deviations.
Lead account based education to support REMS compliance on all aspects of the TOUCH Prescribing Program
Strategically deploys unique resources within Biogen suite of services based on customer need, examples include CMM, Tec NE, Proactive PA Renewal services.
Develops proactive One Biogen Key Account strategies by collaborating with Key Account team and aligning on and executing pull through strategy.
Responsible for collaborating with RAM colleagues for the process integration of ACPs within assigned Key Accounts.
Comfortable leading cross functionally and influencing without authority
Ensures Timely follow-up that demonstrates urgency to both the account and the patient.
Strong problem solving and analytical skills.
Demonstrates strong EQ skills.
Proficiency with Biogen support platforms (i.e. TOUCH ONLINE, QLIKSENSE, VEEVA, Disposition reports, etc).
Qualifications
Minimum 5-7+ years of pharmaceutical/biotech experience
o Ideally 2+ years of experience in the MS Disease State or other related chronic disease
A successful track record in field reimbursement, clinical education or in pharmaceutical sales/management of products that required significant payer and reimbursement involvement
Comprehensive understanding of all aspects of reimbursement (coding, coverage, and payment) including advanced understanding of reimbursement with products under Medical and Pharmaceutical benefits.
Proficiency with distribution through Specialty Pharmacy and Wholesale Distributors through Buy and Bill.
Technical knowledge of healthcare reimbursement from a patient and provider perspective
Experience navigating complex accounts with the ability to establish effective relationships through mutual respect and trust in dealing with others.
Must be comfortable with ambiguity and not having set processes and structures in place
An in-depth understanding and knowledge of FDA mandated Risk Map programs.
Can identify issues quickly and can develop recommendations to resolve in a timely, compliant manner.
Strong presentation skills. Ability to clearly and succinctly convey his/her ideas to either groups or individuals
Strong regional and national Managed Care knowledge
Strong organizational and communication skills- ability to navigate communication between BIIB and the HCP office
Understanding of patient privacy laws including HIPAA and similar state laws
Advanced understanding of compliance with OIG & regulatory requirements.
Driving is an essential duty of this job; candidates must have a valid drivers license to be considered.
Education :
BS/BA Required
MBA Preferred
Additional Information
All your information will be kept confidential according to EEO guidelines.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.